An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

Central Hospital, Nancy, France119 enrolled

Overview

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis

Study Type

OBSERVATIONAL

Enrollment

119

Conditions

Inflammatory Bowel Diseases

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients consulted at the Gastroenterology services of Nancy University Hospital during the period of inclusion 2. Patients over 18 of age the day of consultation 3. Patients treated at least one time by biotherapy during the last 12 months preceeding inclusion 4. Patients with crohn's disease or ulcerative colitis. 5. Patients accepting to respond to the questionnary Exclusion Criteria: * Age under 18 years , the day of consultation * Patient that not accept or unable to complete the retrospective questionnary

Outcomes

Primary Outcomes

Retrospective health care consumption

Desease treatment cost individual level data

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.